Eight notices of allowance and five new patents granted in key international jurisdictions LONDON, May 25, 2023 (GLOBE NEWSWIRE) — Small Pharma Inc. (TSXV: (OTCQB: DMT) A biotechnology company that focuses on short-term psychedelic-assisted therapies for mental health conditions, DMTTF) (the “Company” or “Small Pharma”) today announces an update to its intellectual property (“IP”) portfolio, demonstrating significant progress the Company has already made in 2023.
A multi-layered intellectual property (IP) strategy with four primary areas of protection is Small Pharma’s goal for safeguarding its pipeline programs. The following are protected areas: Piece of Issue, covering novel medication substances; Therapeutic Compositions and Their Medical Uses, including Product of a drug, including drug formulations; also, Manufactured Course, covering the novel and effective combination of high immaculateness drug substance at scale.
The company has acquired five new granted patents since the previous IP portfolio update on February 1, 2023, with three more anticipated to be granted by May 31, 2023. In addition, it has received five Notices of Allowance for patents. The extra IP covers the four centered areas of assurance and various business sectors, fortifying the Organization’s worldwide IP position.
The following is a summary of the new patent grants and Notices of Allowance.
|For certain deuterated homologues of certain tryptamine compounds||USA||11,578,039||Granted|
|For certain deuterated homologues of certain tryptamine compounds||New|
|For certain deuterated analogues of N,N, dimethyltryptamine (“DMT”)||GB||2 592 822||Grant expected|
after May 22, 2023
|For a group of deuterated homologues of DMT||USA||11,660,289||Grant expected on|
May 30, 2023
|For a group of deuterated homologues of DMT||Europe||4 031 529||Notice of|
|Medical Use||Of certain deuterated analogues of DMT||GB||2 586 940||Grant expected|
after May 25, 2023
|Medical use and therapeutic compositions of a group of deuterated homologues of DMT||Australia||2021204158||Notice of|
|Medical use and therapeutic compositions of a group of deuterated homologues of DMT||New Zealand||794833||Notice of|
|Therapeutic compositions of a group of deuterated homologues of DMT||Japan||2022-574099||Notice of|
|Drug Product||Novel optimized injectable formulation of DMT based compounds||Australia||2021334933||Granted|
|Therapeutic solid dosage forms of deuterated DMT analogues||GB||2 595 776||Granted|
|Synthetic Route ||Novel efficient synthesis of high purity DMT and deuterated DMT analogues at scale||USA||11,643,390||Granted|
|Novel efficient synthesis of high purity DMT and deuterated DMT analogues at scale||Canada||3160337||Notice of|
As of May 24, 2023, Little Pharma’s IP portfolio comprises of 19 conceded licenses, with 97 permitted or forthcoming. The protection that applies to each pipeline program of the company is outlined below.
|Candidate / Project||Relevant Patents in Portfolio |
(No. active patents / pending patent applications)
|SPL0261, SPL0282, SPL0293||4 granted patents and 31 allowed and pending applications|
|SPL028||6 granted patents, 37 allowed and pending applications|
|SPL028, SPL029||8 allowed and pending applications|
|SPL029||4 granted patents, 11 allowed and pending applications|
|Non-psychedelic / other||5 granted patents, 10 allowed and pending applications|
1Intravenous or intramuscular DMT
2 Injectable deuterated DMT series
3 Oral tryptamine series
George Tziras, CEO of Little Pharma said: ” Our group has gained extraordinary headway this year to additionally reinforce our exclusive IP position in key worldwide business sectors. Each of our pipeline programs continues to be protected by multiple layers of intellectual property, enhancing their commercial potential. We are pleased that multiple jurisdictions continue to recognize our efforts to invest in the creation of novel treatment innovations for patients.
About Small Pharma: Small Pharma is a biotechnology company working on a pipeline of short-term psychedelic-assisted treatments for mental health issues. At the moment, the company’s primary focus is on investigating novel depression treatment options. Little Pharma’s lead competitor, SPL026, is a restrictive manufactured detailing of N, N-dimethyltryptamine. The U.K. Medicines and Healthcare Products Regulatory Agency (the “MHRA”) awarded the company with an Innovation Passport designation for IV SPL026 with supportive therapy for Major Depressive Disorder. The company is working to advance the clinical programs of SPL026 and SPL028 for the treatment of mental health conditions. Likewise, Little Pharma has a pipeline of exclusive preclinical resources being developed.
Source – Finance.yahoo